Almost All Top German OTC Companies Have Now Raised Prices Due To Inflation – Sempora
Executive Summary
87 of the top 100 German OTC manufacturers are now reporting inflation-driven price increases, up from 72 at the same point last year. Sempora Consulting suggests a number of strategies to address the current economic challenges companies face.
You may also be interested in...
Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut
Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.
Stada Enjoys Strong First Half With Sales Up By A Quarter
A combination of acquisitions, market share gains and successful product launches helped push Stada’s Consumer Healthcare sales up by a quarter in the first half as the German firm weathered tough macroeconomic conditions.
Inflation, Supply Chain And Private Label Pressures: Consumer Health Leaders Talk ‘Big Picture’ Challenges
OTC drug and dietary supplement companies continue to face significant economic and competitive issues in what continues to be a highly volatile operating environment. Here we’ve culled takes from top execs at Sanofi, Bayer, J&J, P&G and other leading players, provided during recent sales and earnings presentations.